DBV Technologies shares break through their €2.07 resistance level, then pull back
The Châtillon-based biotech continues its rebound during the session, in a Parisian market that is rising modestly. The move is part of a US regulatory file that remains open and a financial position under close watch.
A resistance level broken, then lost, after a sharp one-month rebound
The stock gains 2.69% to €2.06, among the strongest gains in the SBF 120. During the session, it broke above its €2.07 resistance level up to an intraday high of €2.11, before slipping slightly back below it. This rebound extends a 22.77% recovery over one month, while the share price remains below its 200-day moving average (€2.84) and is still down 15.92% over three months.
Above its 20-day moving average (€1.78), it has so far regained short-term support. For reference, the stock is listed in Paris and, in the form of ADS, on the Nasdaq: DBV Technologies remains one and the same security across two exchanges, the Paris line being the most liquid.
Third-quarter results, peanut patch and selling pressure in the background
When it published its nine-month 2026 results on 28 October, the company reported substantial doubt about its ability to continue as a going concern over the next twelve months, and a need for additional capital beyond the third quarter of 2027. The $64.5 million loss for the quarter reflects the cost of the shift toward a commercial organisation.
On the regulatory front, the application for authorisation of the Viaskin Peanut patch for children aged 4 to 7 has been filed with the US health authority, with a decision expected in the fourth quarter of 2026 if priority review is granted.
Reported net short positions reach 3.39% of share capital, spread across five funds, up 0.10 points over one month: modest bearish pressure, far from a massive loss of confidence. The €2.07 resistance level remains the reference level for the session.
